Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Facebook Inc (FB), LinkedIn Corp (LNKD): Stay Away From These Social Giants…For Now

Page 1 of 2

I heard it when the company came public. So many people wanted to buy Facebook Inc (NASDAQ:FB) stock. In fact, many people were talking about buying Facebook stock on Facebook itself. How has that worked out for them? Uh…not so well. S&P 500 up 28% (not even including dividends), Facebook Inc (NASDAQ:FB) down 36%.

Now, the stock sits under $25 (as of this writing). And what do I hear again?  People wanting to buy Facebook Inc (NASDAQ:FB) stock because it’s so “low.” Since I’ve had so many people ask me about it, let’s lay it out and put it in perspective.


By now, everybody knows how terrible the IPO was. It opened just shy of $40 and headed straight down, not stopping until the stock value had been cut in half. A bad IPO does not necessarily doom a stock forever. Remember that this is an actual company with real operations. If the stock price had opened around $20 or so, it might still be an underperformer, but people wouldn’t be crying so much. Let’s not beat-up the company simply over a bad IPO.

Facebook Inc (NASDAQ:FB)

Market cap

We start to run into trouble when we look at the market cap. Currently, Facebook Inc (NASDAQ:FB) has a market cap over $59 billion. For perspective, I could total the market caps of LinkedIn Corp (NYSE:LNKD) (more on them later),, inc. (NYSE:CRM), and Citrix Systems, and still not come up with $59 billion of market cap. Say what you will about those three companies, but why would I think that Facebook is worth more than all three of them combined when it hasn’t proven long-term profitability?


One of the biggest problems with Facebook is that it’s already reached a very high user count. It’s not like there is a vast market (aside from China) that is untapped for them. Facebook Inc (NASDAQ:FB) is trying to figure out how to monetize the network it already has. The situation would be far better if it had already monetized it and was working on expanding its network.

The problem is that Facebook now has to figure out not only how to monetize its network, but it also has to figure out how to keep its network. There’s plenty of competition from other companies. Those companies haven’t reached Facebook’s scale yet, but that doesn’t mean they won’t try.


It’s tempting for investors to gravitate to the P/E ratio to start most valuation discussions. However, in a company that is valued for high-growth (whether it should be or not), the P/E can be misleading, especially when it is sky-high. The problem here is that such situations are generally reserved for small companies in the early stages of their growth. They may not have much earnings because they are building an infrastructure, or spending a ton on marketing efforts. Facebook should be well past that point given its scale.

Regardless, I won’t belabor the P/E issue, but instead look to a simpler metric: Price-to-Sales. Unless you’re subject to some goofy accounting rules, revenue doesn’t lie. So, it’s a bit easier to compare the company’s price to its sales. In this case, Facebook Inc (NASDAQ:FB)’s Price-to-Sales is a staggering 10.8! Since I promised some perspective, here are the Price-to-Sales for some other companies:

Apple – 2.5

Microsoft – 3.8

Google – 5.4

LinkedIn – 16.9, inc. (NYSE:CRM) – 7.7

Citrix – 4.6

Again, you’re paying quite a premium in hopes that Facebook can hit it big and figure out how to monetize its network…quickly. That’s not a risk I’m willing to take until it can show some better growth. A good product and a lot of users don’t automatically convert into dollars.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!